Product Information
TRIJARDY XR 5-2.5-1,000 MG TAB is a brand product labeled by Boehringer Ingelheim Pharmaceuticals Inc., priced at $5.6686 per EA under NDC 00597039582. Its NADAC has been published 224 times since Jun 22, 2022.
FDA first approved this application on Jan 27, 2020.
Strength
5; 2.5; 1000 mg/1; mg/1; mg/1
Manufacturer
Boehringer Ingelheim Pharmaceuticals Inc.NDC
00597039582
Classification
Brand
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA212614FDA Approved
1/27/2020
On Market Since
4/23/2020
Pharmacological Classes
Price Statistics
The NADAC for TRIJARDY XR 5-2.5-1,000 MG TAB has been published 224 times since Jun 22, 2022, and over the history we have for it it has declined 37.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $5.6686 per EA |
|---|---|
| All-time high | $10.1459 (Dec 31, 2025) |
| All-time low | $5.6418 (Jan 7, 2026) |
| 52-week high | $10.1459 |
| 52-week low | $5.6418 |
| Median price | $9.5110 |
| Average price | $9.0094 |
| Largest weekly change | -44.4% (Jan 7, 2026) |
| Weeks tracked | 224 |
| Tracking since | Jun 22, 2022 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Boehringer Ingelheim Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
empagliflozin, linagliptin, metformin hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Biguanide class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TRIJARDY XR 5-2.5-1,000 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for TRIJARDY XR 5-2.5-1,000 MG TAB, manufactured by Boehringer Ingelheim Pharmaceuticals Inc., is $5.6686 per EA (NDC 00597039582), effective Sep 30, 2026.
How has the price of TRIJARDY XR 5-2.5-1,000 MG TAB changed over time?
Over the history we have for it, the NADAC for TRIJARDY XR 5-2.5-1,000 MG TAB has declined 37.9%. It has been tracked across 224 weekly CMS publications since Jun 22, 2022.
What are the highest and lowest recorded NADAC prices for TRIJARDY XR 5-2.5-1,000 MG TAB?
Since Jun 22, 2022, the NADAC for TRIJARDY XR 5-2.5-1,000 MG TAB has ranged from a low of $5.6418 (Jan 7, 2026) to a high of $10.1459 (Dec 31, 2025), with a median of $9.5110 per EA.
Are there cheaper alternatives to TRIJARDY XR 5-2.5-1,000 MG TAB?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as TRIJARDY XR 5-2.5-1,000 MG TAB in a comparable dosage form, but none are currently priced below it.
Who manufactures TRIJARDY XR 5-2.5-1,000 MG TAB?
TRIJARDY XR 5-2.5-1,000 MG TAB (NDC 00597039582) is labeled by Boehringer Ingelheim Pharmaceuticals Inc., and CMS classifies it as a brand product.